Published in J Alzheimers Dis on January 01, 2010
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci (2011) 1.09
Evidence of a novel gene HERPUD1 in polypoidal choroidal vasculopathy. Int J Clin Exp Pathol (2015) 0.75
Genomic deletion of GIT2 induces a premature age-related thymic dysfunction and systemic immune system disruption. Aging (Albany NY) (2017) 0.75
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA (1995) 11.45
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA (2002) 8.11
Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol (1998) 4.48
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest (2001) 2.45
Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci (2002) 2.14
Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress. J Biol Chem (2000) 1.98
Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model. Hum Mol Genet (2005) 1.52
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci (2005) 1.43
Homocysteine and Alzheimer's disease. Lancet Neurol (2003) 1.33
Herp stabilizes neuronal Ca2+ homeostasis and mitochondrial function during endoplasmic reticulum stress. J Biol Chem (2004) 1.21
Herp enhances ER-associated protein degradation by recruiting ubiquilins. Biochem Biophys Res Commun (2008) 1.18
Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res (2010) 1.18
Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem (2001) 1.17
B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci (2008) 1.17
Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol (2000) 1.14
A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. J Neurochem (2007) 1.13
Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein. J Biol Chem (2002) 1.09
Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis (2006) 1.04
Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis (2007) 1.04
The ubiquitin-like domain of Herp is involved in Herp degradation, but not necessary for its enhancement of amyloid beta-protein generation. FEBS Lett (2003) 1.01
Hyperhomocysteinemia in dementia. J Neural Transm (Vienna) (2000) 0.93
Cardiovascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr (2008) 0.91
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80
Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res (2002) 2.35
5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo. Ann Neurol (2010) 2.06
Paradoxical absence of a prothrombotic phenotype in a mouse model of severe hyperhomocysteinemia. Blood (2011) 2.02
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J (2007) 1.97
Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res (2009) 1.88
The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging (2006) 1.82
Production of the neuromodulator H2S by cystathionine beta-synthase via the condensation of cysteine and homocysteine. J Biol Chem (2004) 1.77
Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood (2011) 1.77
COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res (2003) 1.72
Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 1.70
Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ Res (2004) 1.68
Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model. Hum Mol Genet (2005) 1.52
Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J (2003) 1.47
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
Antioxidants for Alzheimer disease. JAMA Neurol (2013) 1.38
Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.34
The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. J Biol Chem (2007) 1.34
Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J (2008) 1.32
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.31
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J (2005) 1.30
Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation (2009) 1.30
Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase. Am J Pathol (2011) 1.28
Tsc1+ and tsc2+ regulate arginine uptake and metabolism in Schizosaccharomyces pombe. J Biol Chem (2004) 1.28
Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry (2010) 1.25
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol (2005) 1.23
The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid Redox Signal (2005) 1.20
Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res (2012) 1.18
Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J Biol Chem (2003) 1.16
Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem (2002) 1.14
Chemical chaperone rescue of mutant human cystathionine beta-synthase. Mol Genet Metab (2007) 1.14
A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. J Neurochem (2007) 1.13
Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease. J Alzheimers Dis (2012) 1.13
Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene (2004) 1.11
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation (2004) 1.10
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem (2004) 1.10
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci (2011) 1.09
Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol (2004) 1.09
Cystathionine beta-synthase p.S466L mutation causes hyperhomocysteinemia in mice. Hum Mutat (2008) 1.08
Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J (2009) 1.07
Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol (2009) 1.05
Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One (2013) 1.05
Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res (2009) 1.04
Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase. Proteins (2010) 1.03
Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone. J Biol Chem (2008) 1.03
Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol (2011) 1.02
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res (2004) 1.02
S-adenosylhomocysteine, but not homocysteine, is toxic to yeast lacking cystathionine beta-synthase. Mol Genet Metab (2002) 1.00
Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arterioscler Thromb Vasc Biol (2010) 0.99
Functional rescue of mutant human cystathionine beta-synthase by manipulation of Hsp26 and Hsp70 levels in Saccharomyces cerevisiae. J Biol Chem (2008) 0.96
Dietary intake of S-(alpha-carboxybutyl)-DL-homocysteine induces hyperhomocysteinemia in rats. Nutr Res (2010) 0.95
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res (2008) 0.95
Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am J Pathol (2005) 0.95
Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol (2012) 0.95
Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J (2010) 0.94
Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol (2006) 0.94
Coxibs and Alzheimer's disease: should they stay or should they go? Ann Neurol (2006) 0.94
Cystathionine beta-synthase deficiency causes fat loss in mice. PLoS One (2011) 0.93
Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett (2006) 0.92
Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscler Thromb Vasc Biol (2010) 0.92
Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2alpha-III: evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation (2005) 0.92
Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells. Cancer Biol Ther (2012) 0.91
Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler Thromb Vasc Biol (2007) 0.91
Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis (2005) 0.91
Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res (2005) 0.91
Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One (2011) 0.90
Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation (2003) 0.90
The 5-lipoxygenase as a common pathway for pathological brain and vascular aging. Cardiovasc Psychiatry Neurol (2009) 0.90
12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat (2005) 0.90
Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol (2014) 0.89
Vitamin E in aging, dementia, and Alzheimer's disease. Biofactors (2012) 0.89
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70. PLoS Genet (2010) 0.89
The involvement of 5-lipoxygenase activating protein in anxiety-like behavior. J Psychiatr Res (2013) 0.89
Knockout of 5-lipoxygenase results in age-dependent anxiety-like behavior in female mice. PLoS One (2011) 0.89
5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. Biol Psychiatry (2013) 0.88
Methionine-deficient diet induces post-transcriptional downregulation of cystathionine β-synthase. Nutrition (2009) 0.88
Quantitation of cellular metabolic fluxes of methionine. Anal Chem (2014) 0.87
The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. Aging Cell (2013) 0.87
The methionine salvage pathway compound 4-methylthio-2-oxobutanate causes apoptosis independent of down-regulation of ornithine decarboxylase. Biochem Pharmacol (2006) 0.87
Brain phenotype of transgenic mice overexpressing cystathionine β-synthase. PLoS One (2012) 0.87
The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biol Psychiatry (2013) 0.87
Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genet Med (2004) 0.86
5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging (2013) 0.86
Total synthesis of isoprostanes: discovery and quantitation in biological systems. Chem Phys Lipids (2004) 0.86
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation (2012) 0.85
Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency. J Cell Biochem (2008) 0.85
Cystathionine β-synthase-deficient mice thrive on a low-methionine diet. FASEB J (2013) 0.85
High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays. Cancer Genet Cytogenet (2006) 0.84
Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. Aging Cell (2013) 0.83
Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria. Exp Mol Med (2006) 0.83
Increase in peripheral oxidative stress during hypercholesterolemia is not reflected in the central nervous system: evidence from two mouse models. Neurochem Int (2005) 0.81
Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae. J Biomol Screen (2010) 0.80
Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood (2006) 0.80
A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol (2007) 0.80
Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition. Atherosclerosis (2009) 0.80
Germline Mutations in Mtap Cooperate with Myc to Accelerate Tumorigenesis in Mice. PLoS One (2013) 0.79
Severe In vivo hyper-homocysteinemia is not associatedwith elevation of amyloid-beta peptides in the Tg2576 mice. J Alzheimers Dis (2010) 0.78
Inhibition of betaine-homocysteine S-methyltransferase in rats causes hyperhomocysteinemia and reduces liver cystathionine β-synthase activity and methylation capacity. Nutr Res (2011) 0.77